Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hull

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Research Square|July 17, 2025
Identification of initial sites of SIV rebound after treatment cessationLouis Picker, Brandon Keele, Afam Okoye, et al.
The Journal of Clinical Investigation|January 19, 2021
Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapyAdrienne E Swanstrom, Taina T Immonen, Kelli Oswald, et al.
JCI Insight|June 7, 2019
TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremiaGregory Q Del Prete, W Gregory Alvord, Yuan Li, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Plos Pathogens|August 22, 2024
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistenceBenjamin Varco-Merth, Morgan Chaunzwa, Derick M Duell, et al.
Science Immunology|June 17, 2022
Myeloid cell tropism enables MHC-E-restricted CD8<sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccineScott G Hansen, Meaghan H Hancock, Daniel Malouli, et al.
Science Immunology|March 26, 2021
Cytomegaloviral determinants of CD8<sup>+</sup> T cell programming and RhCMV/SIV vaccine efficacyDaniel Malouli, Scott G Hansen, Meaghan H Hancock, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Research Square|July 17, 2025
Identification of initial sites of SIV rebound after treatment cessationLouis Picker, Brandon Keele, Afam Okoye, et al.
The Journal of Clinical Investigation|January 19, 2021
Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapyAdrienne E Swanstrom, Taina T Immonen, Kelli Oswald, et al.
JCI Insight|June 7, 2019
TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremiaGregory Q Del Prete, W Gregory Alvord, Yuan Li, et al.
Science (New York, N.Y.)|March 26, 2021
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacyMarieke C Verweij, Scott G Hansen, Ravi Iyer, et al.
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Plos Pathogens|August 22, 2024
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistenceBenjamin Varco-Merth, Morgan Chaunzwa, Derick M Duell, et al.
Science Immunology|June 17, 2022
Myeloid cell tropism enables MHC-E-restricted CD8<sup>+</sup> T cell priming and vaccine efficacy by the RhCMV/SIV vaccineScott G Hansen, Meaghan H Hancock, Daniel Malouli, et al.
Science Immunology|March 26, 2021
Cytomegaloviral determinants of CD8<sup>+</sup> T cell programming and RhCMV/SIV vaccine efficacyDaniel Malouli, Scott G Hansen, Meaghan H Hancock, et al.
Pageof 7